RxDoctor Payments Data

Robert Aylesworth, MD

Dermatology · Rhinelander, WINPI 1356397699

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,045 of the $5,817 with a category attached, or 69.5%. 21 manufacturers reported payments, led by Johnson & Johnson at 27.2% of the total.

$5,817in general payments, 2019–2025

Across 223 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$935
  • Regeneron Healthcare Solutions, Inc.$650
  • Lilly USA, LLC$492
  • Sanofi$307
  • Sun Pharmaceutical Industries Inc.$282
  • plus $2K from 15 others
$13,110in research payments, 2019–2025

Across 10 payments — averaging $1311.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$13K

What the payments were for

  • Consulting fees$1,20021%
  • Food & beverage$4,04570%
  • Education$57210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,817 in reported general payments places this provider in the 85th percentile of 260 dermatology providers in Wisconsin.

See all dermatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$602,907
Medicare patients
1,831
Services billed
13,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$407,201
Taltz AutoinjectorIxekizumab40$268,964
Cosentyx Sensoready (2 Pens)Secukinumab12$90,508
Dupixent PenDupilumab14$51,490
Dupixent SyringeDupilumab14$51,243
Doxycycline Monohydrate240$7,638
Clobetasol Propionate167$6,416
Triamcinolone Acetonide428$4,591
Acitretin12$2,791
Dapsone27$2,649
Minoxidil121$2,301
MethotrexateMethotrexate Sodium93$2,159
Betamethasone Valerate29$1,087
Minocycline Hcl36$1,020
Fluorouracil14$850

Paid to pharmacies, not to this prescriber.

Other dermatology in Rhinelander

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →